Sarepta Therapeutics stockholders approve equity plan increase and elect four directors
At its annual meeting on June 5, 2025, Sarepta Therapeutics stockholders approved an increase of 4,300,000 shares to the 2018 Equity Incentive Plan, bringing the total to 17,487,596 shares, and a 300,000-share increase to the employee stock purchase plan, bringing it to 1,700,000 shares. Stockholders also re-elected four Class II directors, approved executive pay on an advisory basis, and ratified KPMG LLP as auditor for 2025. The larger share reserves govern how many shares can be issued under those plans.
Key points
- Stockholders approved a 4,300,000-share increase to the 2018 Equity Incentive Plan, to 17,487,596 shares in total.
- Stockholders approved a 300,000-share increase to the employee stock purchase plan, to 1,700,000 shares in total.
- Richard J. Barry received 64,757,685 For votes and 9,565,547 Against; Stephen L. Mayo, Ph.D. received 73,289,653 For votes and 1,051,656 Against.
- On the advisory pay vote, 72,144,292 shares were For and 2,176,998 Against; KPMG LLP was ratified with 80,588,115 For and 3,875,497 Against.
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.